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Objectives We performed the long-term follow-up of a large cohort of patients in a multicenter study receiving left main
coronary artery (LMCA) revascularization.
Background Limited information is available on long-term outcomes for patients with unprotected LMCA disease who under-
went coronary stent procedure or coronary artery bypass grafting (CABG).
Methods We evaluated 2,240 patients with unprotected LMCA disease who received coronary stents (n  1,102; 318
with bare-metal stents and 784 with drug-eluting stents) or underwent CABG (n  1,138) between 2000 and
2006 and for whom complete follow-up data were available for at least 3 to 9 years (median 5.2 years). The
5-year adverse outcomes (death; a composite outcome of death, Q-wave myocardial infarction [MI], or stroke;
and target vessel revascularization [TVR]) were compared with the use of the inverse probability of treatment
weighted method and propensity-score matching.
Results After adjustment for differences in baseline risk factors with the inverse probability of treatment weighting, the
5-year risk of death (hazard ratio [HR]: 1.13; 95% confidence interval [CI]: 0.88 to 1.44, p  0.35) and the com-
bined risk of death, Q-wave MI, or stroke (HR: 1.07; 95% CI: 0.84 to 1.37, p  0.59) were not significantly differ-
ent for patients undergoing stenting versus CABG. The risk of TVR was significantly higher in the stenting group
than in the CABG group (HR: 5.11; 95% CI: 3.52 to 7.42, p  0.001). Similar results were obtained in compari-
sons of bare-metal stent with concurrent CABG and of drug-eluting stent with concurrent CABG. In further analy-
sis with propensity-score matching, overall findings were consistent.
Conclusions During 5-year follow-up, stenting showed similar rates of mortality and of the composite of death, Q-wave MI, or
stroke but higher rates of TVR as compared with CABG for patients with unprotected LMCA disease. (J Am Coll
Cardiol 2010;56:117–24) © 2010 by the American College of Cardiology Foundation
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Stenting Versus CABG for LMCA Disease July 6, 2010:117–24Although coronary artery bypass
grafting (CABG) has been rec-
ommended as the standard treat-
ment for patients with unpro-
tected left main coronary artery
(LMCA) disease (1), percutane-
ous coronary intervention (PCI)
of an unprotected LMCA has
increased in frequency together
with improvements in interven-
tional techniques and adjunctive
drug therapy (2). Several studies
have suggested that coronary
stenting has been shown to be
feasible for patients with unpro-
tected LMCA stenosis (3). In
addition, the application of PCI
o LMCA disease has increased further with the availability
f drug-eluting stents (DES) that significantly reduce the
ates of restenosis and repeat revascularization (4–6). How-
ver, limited data exist regarding the long-term outcomes of
oronary stenting, as compared with standard CABG, for
hese patients. Furthermore, the long-term safety of DES
as been questioned by recent reports suggesting increased
isk of late stent thrombosis, mortality, or myocardial
nfarction (MI) (7,8). Therefore, very-long-term follow-up
fter DES implantation in a large patient cohort with
MCA disease is important.
The MAIN-COMPARE (Revascularization for Unpro-
ected Left Main Coronary Artery Stenosis: Comparison of
ercutaneous Coronary Angioplasty Versus Surgical Revas-
ularization) registry was designed to evaluate the real-world
utcomes of coronary stenting and CABG for unprotected
MCA disease in multiple centers of Korea, and the
edian 3-year comparative outcomes were previously re-
orted (9). To obtain a more reliable long-term treatment
ffect of stenting or CABG, we have now extended the
ollow-up duration for the study patients, for whom
ollow-up data were available for at least 3 years and up to
years.
ethods
tudy population. The MAIN-COMPARE study en-
olled patients with unprotected LMCA stenosis who un-
erwent either CABG or PCI as the index procedure at 12
r. Seng-Wook Park has received research support from Medtronic. Dr. Hyeon-Cheol
won has received lecture fees from Boston Scientific and Medtronic, and research grant
upport from Medtronic. Dr. Myung-Ho Jeong has received lecture fees from Cordis,
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Abbreviations
and Acronyms
BMS  bare-metal stent(s)
CABG  coronary artery
bypass grafting
CI  confidence interval
DES  drug-eluting stent(s)
HR  hazard ratio
LMCA  left main coronary
artery
MI  myocardial infarction
PCI  percutaneous
coronary intervention
TVR  target vessel
revascularizationw
Manuscript received February 8, 2010; revised manuscript received March 26,
010, accepted April 5, 2010.ajor cardiac centers in Korea between January 2000 and
une 2006 (9). The LMCA was considered unprotected if
here were no patent grafts to the left anterior descending
rtery or circumflex artery. Patients who had prior CABG,
hose who underwent concomitant valvular or aortic sur-
ery, and those who had an ST-segment elevation MI or
resented with cardiogenic shock were excluded.
In this analysis, the follow-up period extended through
ctober 30, 2009, to ensure that all patients had at least 3
ears and approximately up to 9 years of follow-up infor-
ation. From January 2000 through May 2003, coronary
tenting was performed exclusively with bare-metal stents
BMS), whereas from May 2003 through June 2006, DES
ere used exclusively. Therefore, the relative treatment
ffects were evaluated in the overall cohort, pre-DES cohort
Wave 1 of the registry; BMS vs. concurrent CABG
etween January 2000 and May 2003), and post-DES
ohort (Wave 2 of the registry; DES vs. concurrent CABG
etween May 2003 and June 2006).
The local ethics committee at each hospital approved the
se of clinical data for this study, and all patients provided
ritten informed consent.
evascularization procedures. Patients underwent PCI,
nstead of CABG, because of either the patient’s or physi-
ian’s preference or the high risk associated with CABG.
ethods of stent implantation for patients with LMCA
isease have been described previously (10,11). All proce-
ures were performed with standard interventional tech-
iques. The use of pre-dilation, intra-aortic balloon pump,
r intravascular ultrasound and the choice of the specific
ype of DES was at the operator’s discretion. Antiplatelet
herapy and periprocedural anticoagulation followed stan-
ard regimens. After the procedure, aspirin was continued
ndefinitely. Patients treated with BMS were prescribed
iclopidine (250 mg twice/day) for at least 1 month, and
atients treated with DES were prescribed clopidogrel (75
g once/day) for at least 6 months, regardless of DES type.
reatment beyond this duration was at the discretion of the
hysician. Surgical revascularization was performed with the
se of standard bypass techniques (12). Complete revascu-
arization was performed when possible with arterial con-
uits or saphenous vein grafts.
tudy outcomes and follow-up. The end points of the
tudy were death; the composite of death, Q-wave MI, or
troke; and target vessel revascularization (TVR). Death was
efined as death from any cause. Q-wave MI was defined as
ocumentation of a new abnormal Q-wave after the index
evascularization. Stroke, as indicated by neurologic deficits,
as confirmed by a neurologist on the basis of imaging
tudies. A TVR was defined as any repeat revascularization
n any left anterior descending artery or left circumflex artery
s well as in the target segment. In the PCI group, stent
hrombosis was defined as the definite occurrence of a
hrombotic event, according to the Academic Research
onsortium classification (13). All outcomes of interest
ere confirmed by source documentation collected at each
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July 6, 2010:117–24 Stenting Versus CABG for LMCA Diseaseospital and were centrally adjudicated by an independent
roup of clinicians.
Clinical, angiographic, procedural or operative, and out-
ome data were recorded in the dedicated PCI and surgical
atabases by independent research personnel. For validation
f complete follow-up data, information about vital status
as obtained from the National Population Registry of the
orea National Statistical Office with the use of a unique
ersonal identification number. Routine angiographic
ollow-up was recommended for all PCI patients at 6 to 10
onths or earlier if clinically indicated. For CABG patients,
aseline CharacteristicsTable 1 Baseline Characteristics
Overall Patients
(n  2,240)
Variable
Stents
(n  1,102)
CABG
(n  1,138) p Valu
Demographic characteristics
Age (yrs) 61.3 11.7 62.9 9.4 0.00
Male sex 779 (70.7) 830 (72.9) 0.24
Cardiac or coexisting conditions
Diabetes mellitus
Any diabetes 327 (29.7) 395 (34.7) 0.01
Requiring insulin 75 (6.8) 93 (8.2) 0.22
Hypertension 546 (49.5) 562 (49.4) 0.94
Hyperlipidemia 314 (28.5) 371 (32.6) 0.04
Current smoker 282 (25.6) 339 (29.8) 0.03
Previous coronary angioplasty 200 (18.1) 125 (11.0) 0.00
Previous myocardial infarction 89 (8.1) 132 (11.6) 0.00
Previous congestive heart failure 27 (2.5) 38 (3.3) 0.21
Chronic obstructive pulmonary disease 22 (2.0) 23 (2.0) 0.97
Cerebrovascular disease 78 (7.1) 83 (7.3) 0.84
Peripheral vascular disease 16 (1.5) 62 (5.4) 0.00
Renal failure 30 (2.7) 34 (3.0) 0.71
Ejection fraction (%) 60.6 10.8 57.2 11.9 0.00
Electrocardiographic findings 0.53
Sinus rhythm 1,079 (97.8) 1,105 (97.1)
Atrial fibrillation 22 (2.0) 31 (2.7)
Other 2 (0.2) 2 (0.2)
Clinical indication 0.00
Silent ischemia 33 (3.0) 25 (2.2)
Chronic stable angina 353 (32.0) 226 (19.9)
Unstable angina 608 (55.2) 775 (68.1)
NSTEMI 108 (9.8) 112 (9.8)
Angiographic characteristics
Involved location 0.04
Ostium and/or mid-shaft 557 (50.6) 526 (46.2)
Distal bifurcation 545 (49.5) 612 (53.8)
Extent of diseased vessel 0.00
Left main only 278 (25.2) 71 (6.2)
Left main plus single-vessel disease 264 (24.0) 119 (10.5)
Left main plus double-vessel disease 287 (26.0) 299 (26.3)
Left main plus triple-vessel disease 273 (24.8) 649 (57.0)
Right coronary artery disease 396 (35.9) 804 (70.7) 0.00
Restenotic lesion 32 (2.9) 14 (1.2) 0.00
ata are shown as mean  SD for continuous variables and absolute numbers (%) for dichotomo
ypass grafting (CABG), and Wave 2 shows comparisons of drug-eluting (DES) stents versus concurrent C
NSTEMI  non–ST-segment elevation myocardial infarction.ngiographic follow-up was recommended only if there
ere ischemic symptoms or signs during follow-up.
tatistical analysis. Continuous variables were compared
ith the t test or Wilcoxon rank sum tests, and categorical
ariables were compared with the chi-square statistics or
isher exact test, as appropriate. Survival curves were
onstructed with Kaplan-Meier estimates and compared
ith the log-rank test.
To reduce the impact of treatment selection bias and
otential confounding in an observational study, we per-
ormed rigorous adjustment for differences in baseline
Wave 1*
(n  766)
Wave 2*
(n  1,474)
BMS
(n  318)
CABG
(n  448) p Value
DES
(n  784)
CABG
(n  690) p Value
8.6 12.6 61.3 9.6 0.001 62.5 11.1 64.0 9.1 0.003
223 (70.1) 331 (73.9) 0.25 556 (70.9) 499 (72.3) 0.55
76 (23.9) 139 (31.0) 0.03 251 (32.0) 256 (37.1) 0.04
11 (3.5) 25 (5.6) 0.17 64 (8.2) 68 (9.9) 0.26
128 (40.3) 219 (48.9) 0.02 418 (53.3) 343 (49.7) 0.17
74 (23.3) 118 (26.3) 0.33 240 (30.6) 253 (36.7) 0.01
89 (28.0) 161 (35.9) 0.02 193 (24.6) 178 (25.8) 0.60
40 (12.6) 46 (10.3) 0.32 160 (20.4) 79 (11.4) 0.001
26 (8.2) 57 (12.7) 0.05 63 (8.0) 75 (10.9) 0.06
7 (2.2) 16 (3.6) 0.27 20 (2.6) 22 (3.2) 0.46
2 (0.6) 5 (1.1) 0.71 20 (2.6) 18 (2.6) 0.94
12 (3.8) 35 (7.8) 0.02 66 (8.4) 48 (7.0) 0.29
2 (0.6) 31 (6.9) 0.001 14 (1.8) 31 (4.5) 0.003
4 (1.3) 10 (2.2) 0.32 26 (3.3) 24 (3.5) 0.86
1.4 10.2 59.2 11.5 0.02 60.3 11.0 55.8 12.0 0.001
0.32 0.67
314 (98.7) 438 (97.8) 764 (97.4) 667 (96.7)
4 (1.3) 10 (2.2) 18 (2.3) 21 (3.0)
0 0 2 (0.3) 2 (0.3)
0.002 0.001
6 (1.9) 12 (2.7) 27 (3.4) 13 (1.9)
86 (27.0) 70 (15.6) 267 (34.1) 156 (22.6)
203 (63.8) 327 (73.0) 405 (51.7) 448 (64.9)
23 (7.2) 39 (8.7) 85 (10.8) 73 (10.6)
0.001 0.15
218 (68.6) 202 (45.1) 339 (43.2) 324 (47.0)
100 (31.4) 246 (54.9) 445 (56.8) 366 (53.0)
0.001 0.001
133 (41.8) 45 (10.0) 145 (18.5) 26 (3.8)
82 (25.8) 65 (14.5) 182 (23.2) 54 (7.8)
70 (22.0) 139 (31.0) 217 (27.7) 160 (23.2)
33 (10.4) 199 (44.4) 240 (30.6) 450 (65.2)
63 (19.8) 266 (59.4) 0.001 333 (42.5) 538 (78.0) 0.001
5 (1.6) 8 (1.8) 0.82 27 (3.4) 6 (0.6) 0.001
bles. *Wave 1 shows comparisons of bare-metal stents (BMS) versus concurrent coronary arterye
1 5
1
5
1
1 6
1
1
1
5
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Stenting Versus CABG for LMCA Disease July 6, 2010:117–24haracteristics of patients by use of the weighted Cox
roportional-hazards regression models with the inverse-
robability-of-treatment weighting (14). With that tech-
ique, weights for patients receiving CABG were the
nverse of (1  propensity score), and weights for patients
eceiving stenting were the inverse of propensity score. The
ropensity scores were estimated without regard to out-
omes, with multiple logistic-regression analysis. A full
onparsimonious model was developed that included all
ariables shown in Table 1. Model discrimination was
ssessed with c-statistics, and model calibration was assessed
ith Hosmer-Lemeshow statistics. For each comparison
the entire cohort, Wave 1, and Wave 2), a separate
ropensity score for PCI versus CABG was derived.
In addition, we also compared outcomes with the use of
ropensity-score matching in the overall cohort and in
eparate subgroups according to type of stent (15). Propen-
ity matching was done with the Greedy algorithm (16), and
omparisons were completed with Cox regression models,
ith robust standard errors that accounted for the clustering
f matched pairs. The details of the propensity-score
atching and analytic methods have been described previ-
usly (9).
All reported p values are 2-sided, and p values of 0.05
ere considered to indicate statistical significance. The SAS
oftware, version 9.1 (SAS Institute, Cary, North Carolina),
nd the R programming language were used for statistical
nalyses.
esults
atient characteristics. Between January 2000 and June
006, a total of 2,240 patients with unprotected LMCA
isease were enrolled; 1,102 patients were treated with PCI
ith stenting (318 with BMS, and 784 with DES), and
,138 were treated with CABG. Of PCI patients, 1,073
97%) had clinical and angiographic conditions that made
hem eligible for either PCI or CABG, but they underwent
CI because of the patient’s or physician’s preference. The
emaining 29 patients (3%) had comorbidities ineligible for
urgery due to old age with poor performance status, limited
ife expectancy, concurrent severe medical illness, or poor
natomic conditions.
Procedural characteristics of the patients in the MAIN-
OMPARE registry have been described previously (9), and
elected features are: 1) among DES patients, 77% received
irolimus-eluting stents, and 23% received paclitaxel-eluting
tents; 2) the mean number of stents implanted in left main
oronary lesions and per-patient (including left main and
ther vessels) was 1.2  0.5 and 1.9  1.1, respectively;
) among CABG patients, 42% underwent off-pump surgery;
nd 4) 98% underwent revascularization of the left anterior
escending artery with an arterial conduit.
The baseline characteristics of the study patients are
hown in Table 1. The CABG patients had a higher-risk
linical and angiographic profile than PCI patients.ollow-up and outcomes. The median follow-up was 62.0
onths (interquartile range 48.0 to 78.3 months) in the
verall patients. Complete follow-up for major clinical
vents was obtained in 97.9% of the overall cohort (98.1%
No. at Risk
Stenting         1102                1063 1032                 994                 804                517            
CABG            1138                1083 1042      997                 879                 684
   Death 
Log-Rank P=0.06 Stenting
CABG
96.6
94.1
91.5 90.0 88.2
95.2
91.9
89.5 87.7 86.4
   Death, Q-wave MI, or Stroke
Log-Rank P=0.03 Stenting
CABG
No. at Risk
Stenting         1102                1050 1020                 983                 795                511            
CABG            1138                1049 1011      969                 854                 662
96.0
93.5
91.0
89.5
87.893.5 90.5
88.3 86.6 85.3
  TVR
Log-Rank P<0.001 Stenting
CABG
No. at Risk
Stenting         1102                 967 919                 868                 694               437            
CABG            1138               1066 1015      964                 847                 654
98.5 97.4 96.8 96.5 96.0
90.8
88.7 86.9 85.8
84.0
A
B
C
Figure 1
Kaplan-Meier Curves for Outcome
in the Overall Patients Who Underwent
Stent Implantation or Bypass Surgery
(A) Overall survival; (B) freedom from death, Q-wave myocardial infarction (MI),
or stroke; (C) target vessel revascularization (TVR). CABG  coronary artery
bypass grafting.
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July 6, 2010:117–24 Stenting Versus CABG for LMCA Diseaseor the PCI group, and 97.6% for the CABG group; p 
.45). During overall follow-up, 328 patients (14.6%) died,
f whom 221 (9.9%) died of a cardiovascular cause. A total
f 22 (1.0%) suffered a Q-wave MI, and 41 (1.8%) suffered
stroke. TVR was performed in 218 (9.7%).
During 5 years of follow-up, the observed (unadjusted)
vent-free survival and crude relative risk according to
reatment approach are presented in Figure 1 and Table 2.
etails regarding the relative risk of stenting according to
ype of stent versus concurrent CABG are also presented
Wave 1 in Fig. 2, and Wave 2 in Fig. 3). There was a trend
oward lower rates of death and significantly lower incidence
f the composite of death, Q-wave MI, or stroke in the PCI
roup than in the CABG group, whereas the rate of TVR
as significantly higher in the PCI group. This trend was
ore prominent in comparison of DES with concurrent
ABG. In 784 patients who received DES, 11 patients had
efinite stent thrombosis. Among them, 1 patient had
cute, 3 had subacute, 3 had late (201, 289, and 350 days
fter the procedure, respectively), and 4 had very late stent
hrombosis (638, 724, 803, and 1,077 days after the proce-
ure, respectively). At 5-year follow-up, the cumulative
ncidence of definite stent thrombosis associated with DES
as 1.5%.
After adjustment of baseline covariates with the inverse-
robability-of-treatment weighting, the 5-year risks of
eath and the composite of death, Q-wave MI, or stroke
ere similar in the 2 groups (Table 2). However, the
djusted risk of TVR was significantly higher in the PCI
roup than in the CABG group. Similarly, in patients
lassified by type of stent, overall results were consistent for
aves 1 and 2.
After performing propensity-score matching in the entire
opulation, a total of 542 matched pairs of patients were
reated; 207 matched pairs of patients with BMS and
HRs for Clinical Outcomes After Stenting as ComTable 2 HRs for Clinical Outcomes After Ste
Outcome H
Overall cohort (n  2,240)
Death 0.
Composite outcome (death, Q-wave MI, or stroke) 0.
TVR 4.
Wave 1† (n  766)
Death 0.
Composite outcome (death, Q-wave MI, or stroke) 0.
TVR 3.
Wave 2† (n  1,474)
Death 0.
Composite outcome (death, Q-wave MI, or stroke) 0.
TVR 4.
*Hazard ratios (HRs) are for the stenting group, as compared with CAB
Wave 2 shows comparisons of DES versus concurrent CABG.
CI  confidence interval; MI  myocardial infarction; TVR  targetoncurrent CABG control subjects in the Wave 1, and 396 tatched pairs of patients with DES and concurrent CABG
ontrol subjects in the Wave 2. In propensity-matching
ethods, there was no significant difference in 5-year rates
f death and a composite of serious outcomes (death,
-wave MI, or stroke) between the 2 groups (Table 3).
owever, the 5-year rate of TVR was consistently higher in
he PCI group than in the CABG group.
iscussion
n this large, multicenter cohort of consecutive patients with
nprotected LMCA disease, there was no significant dif-
erence in the risks of death and a composite outcome of
eath, Q-wave MI, or stroke between the PCI and the
ABG groups during 5 years of follow-up. These results
ere consistent when BMS or DES were compared with
oncurrent CABG. By contrast, the rate of TVR was
ignificantly lower in the CABG group than in the PCI
roup, without regard to type of stent.
Several observational studies and LMCA subsets in the
YNTAX (Synergy between PCI with Taxus and Cardiac
urgery) trial indicated that safety outcomes (death or
omposite of death, MI, or stroke) were comparable be-
ween the PCI and the CABG group, but the advantage of
ABG consists primarily of fewer repeat revascularizations
9,17–25). Although observed findings from subgroup anal-
sis should be interpreted with caution and the interpreta-
ion must be speculative, PCI seemed to be even safer than
ABG in more simple anatomic situations (i.e., lower
YNTAX score tertiles) (26). In addition, a significantly
igher rate of follow-up angiography in the PCI cohort
ue to systematic protocol-driven follow-up in our study
73.0% vs. 14.6% in the CABG cohort, p  0.001) would
nherently bias the PCI population toward TVR, which is
he major difference between the 2 groups. However,
d With After CABGas Compared With After CABG
Unadjusted
Adjusted by Inverse
Probability of
Treatment Weights
5% CI) p Value HR* (95% CI) p Value
5–1.01) 0.06 1.13 (0.88–1.44) 0.35
3–0.97) 0.03 1.07 (0.84–1.37) 0.59
6–5.65) 0.001 5.11 (3.52–7.42) 0.001
4–1.30) 0.62 1.45 (0.95–2.20) 0.08
0–1.21) 0.38 1.27 (0.84–1.92) 0.27
5–5.68) 0.001 4.88 (2.96–8.06) 0.001
5–0.96) 0.02 1.00 (0.73–1.37) 0.99
4–0.95) 0.02 0.99 (0.73–1.36) 0.99
4–7.73) 0.001 6.45 (3.75–11.09) 0.001
p. †Wave 1 shows comparisons of BMS versus concurrent CABG, and
revascularization; other abbreviations as in Table 1.parenting
R* (9
81 (0.6
78 (0.6
09 (2.9
91 (0.6
85 (0.6
58 (2.2
72 (0.5
72 (0.5
85 (3.0
G grouhese early studies with short follow-up periods could
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Stenting Versus CABG for LMCA Disease July 6, 2010:117–24ave penalized the CABG group, because the long-term
enefits of bypass surgery over PCI in other settings have
ot typically been fully evident until 1 to 3 years after the
rocedure (27). The present study extends previous
No. at Risk
BMS                318                 306 296                 291                 281                255             
CABG             448                 426     416    409                 403                 398
   Death 
Log-Rank P=0.62 BMS
CABG
96.2
93.1 91.5 90.0 89.195.1 92.9 91.3
89.9 88.6
   Death, Q-wave MI, or Stroke
Log-Rank P=0.38 BMS
CABG
95.6
92.7 91.1 89.5 88.593.2 91.0 89.6 88.5 87.6
No. at Risk
BMS                318                 292 296                 287                 277                252             
CABG             448                 412     402    396                 391                 386
   TVR
Log-Rank P<0.001 BMS
CABG
97.5 97.0 96.3 96.0 95.0
85.2 84.2 82.9 82.9 82.5
No. at Risk
BMS                318                 261 252                 244                 235                212             
CABG             448                 415     403    393                 387                 378
A
B
C
Figure 2
Kaplan-Meier Curves for Outcome in
Patients Who Underwent Stent Implantation
With BMS or Concurrent Bypass Surgery
(A) Overall survival; (B) freedom from death, Q-wave MI, or stroke;
(C) TVR. BMS  bare-metal stent(s); other abbreviations as in Figure 1.ndings to a longer-term follow-up and demonstrates bhat overall findings were unchanged between 3 and 5
ears of follow-up (9).
We noted, among patients with unprotected LMCA
isease who received DES, a 5-year cumulative stent throm-
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Figure 3
Kaplan-Meier Curves for Outcome in
Patients Who Underwent Stent Implantation
With DES or Concurrent Bypass Surgery
(A) Overall survival; (B) freedom from death, Q-wave MI, or stroke;
(C) TVR. DES  drug-eluting stent(s); other abbreviations as in Figure 1.osis incidence of 1.5%, similar to those reported in several
o
(
w
t
c
c
b
f
a
c
s
u
r
s
S
n
D
f
fi
r
t
S
i
E
A
R
w
m
l
r
s
fi
fi
C
F
s
(
d
t
t
i
c
P
R
D
A
1
R
1
1
1
H
* f DES v
123JACC Vol. 56, No. 2, 2010 Park et al.
July 6, 2010:117–24 Stenting Versus CABG for LMCA Diseasebservations studies with a range between 1% and 2%
28–30). It provides further evidence that LMCA stenting
ith DES results in lower or, at worst, similar rates of stent
hrombosis than rates reported among patients with other
oronary lesions in routine clinical practice (7).
Because of the narrow margin for error, interventional
ardiologists undertaking PCI of LMCA lesions should
e experienced and backed by highly competent support
rom cardiac surgeons. The particulars of clinical practice
s well as the specific expertise of the interventional
ardiologists and the surgical techniques of the cardiac
urgeons in the participating centers might have contrib-
ted to our results (31,32). It might potentially limit the
eproducibility of these results in other institutional
ettings and practitioners.
tudy limitations. First, the inherent limitations of a
onrandomized registry study should be acknowledged.
espite appropriate statistical adjustments, unknown con-
ounders might have affected the results. Therefore, our
ndings should be confirmed or refuted through large
andomized clinical trials with long-term follow-up, such as
he PRECOMBAT (Randomized Comparison of Bypass
urgery Versus Angioplasty Using Sirolimus-Eluting Stent
n Patients With Left Main Coronary Artery Disease) or
XCEL (Evaluation of Xience Prime versus Coronary
rtery Bypass Surgery for Effectiveness of Left Main
evascularization) clinical trials (3). Second, our analysis
as still underpowered to detect significant differences in
ortality and serious composite outcomes. Third, our study
acks detailed information about the burden of atheroscle-
otic disease and anatomic complexity, such as the SYNTAX
core. Finally, because this study evaluated BMS and the
rst-generation of DES, the direct application of these
ndings to the next generation of DES might be limited.
onclusions
or patients with unprotected LMCA disease, PCI with
tenting and CABG were associated with similar long-term
5-year) rates of death and the composite end point of
eath, Q-wave MI, or stroke. Rates of repeat revasculariza-
ion were still higher among patients who underwent PCI
han among those who underwent CABG. A large random-
zed comparison study with CABG will provide more
onfidence in the long-term safety, durability, and efficacy of
Rs for Clinical Outcomes After Stenting as Compared With After CTable 3 HRs for Clinical Outcomes After Stenting as Compared
Overall Patients (n  542
Outcome HR† (95% CI) p
Death 1.02 (0.74–1.39)
Composite outcome (death, Q-wave MI, or stroke) 1.10 (0.74–1.38)
TVR 4.55 (2.88–7.20) 
Wave 1 shows comparisons of BMS versus concurrent CABG, and Wave 2 shows comparisons o
Abbreviations as in Tables 1 and 2.CI with DES.eprint requests and correspondence: Dr. Seung-Jung Park,
ivision of Cardiology, University of Ulsan College of Medicine,
san Medical Center, 388-1 Poongnap-dong, Songpa-gu, Seoul
38-736, Korea. E-mail: sjpark@amc.seoul.kr.
EFERENCES
1. Patel MR, Dehmer GJ, Hirshfeld JW, Smith PK, Spertus JA.
ACCF/SCAI/STS/AATS/AHA/ASNC 2009 appropriateness crite-
ria for coronary revascularization: a report of the American College of
Cardiology Foundation Appropriateness Criteria Task Force, Society
for Cardiovascular Angiography and Interventions, Society of Tho-
racic Surgeons, American Association for Thoracic Surgery, American
Heart Association, and the American Society of Nuclear Cardiology.
J Am Coll Cardiol 2009;53:530–53.
2. Huang HW, Brent BN, Shaw RE. Trends in percutaneous versus
surgical revascularization of unprotected left main coronary stenosis in
the drug-eluting stent era: a report from the American College of
Cardiology-National Cardiovascular Data Registry (ACC-NCDR).
Catheter Cardiovasc Interv 2006;68:867–72.
3. Park SJ, Park DW. Percutaneous coronary intervention with stent
implantation versus coronary artery bypass surgery for treatment of left
main coronary artery disease: is it time to change guidelines? Circ
Cardiovasc Intervent 2009;2:59–68.
4. Park SJ, Kim YH, Lee BK, et al. Sirolimus-eluting stent implantation
for unprotected left main coronary artery stenosis: comparison with
bare metal stent implantation. J Am Coll Cardiol 2005;45:351–6.
5. Valgimigli M, van Mieghem CA, Ong AT, et al. Short- and
long-term clinical outcome after drug-eluting stent implantation for
the percutaneous treatment of left main coronary artery disease:
insights from the Rapamycin-Eluting and Taxus Stent Evaluated At
Rotterdam Cardiology Hospital registries (RESEARCH and
T-SEARCH). Circulation 2005;111:1383–9.
6. Chieffo A, Stankovic G, Bonizzoni E, et al. Early and mid-term results
of drug-eluting stent implantation in unprotected left main. Circula-
tion 2005;111:791–5.
7. Daemen J, Wenaweser P, Tsuchida K, et al. Early and late coronary
stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in
routine clinical practice: data from a large two-institutional cohort
study. Lancet 2007;369:667–78.
8. Lagerqvist B, James SK, Stenestrand U, Lindback J, Nilsson T,
Wallentin L. Long-term outcomes with drug-eluting stents versus
bare-metal stents in Sweden. N Engl J Med 2007;356:1009–19.
9. Seung KB, Park DW, Kim YH, et al. Stents versus coronary-artery
bypass grafting for left main coronary artery disease. N Engl J Med
2008;358:1781–92.
0. Park SJ, Hong MK, Lee CW, et al. Elective stenting of unprotected
left main coronary artery stenosis: effect of debulking before stenting
and intravascular ultrasound guidance. J Am Coll Cardiol 2001;38:
1054–60.
1. Park SJ, Lee CW, Kim YH, et al. Technical feasibility, safety, and
clinical outcome of stenting of unprotected left main coronary artery
bifurcation narrowing. Am J Cardiol 2002;90:374–8.
2. Eagle KA, Guyton RA, Davidoff R, et al. ACC/AHA 2004 guideline
update for coronary artery bypass graft surgery: a report of the
Among Propensity-Matched PatientsAfter CABG Among Propensity-Matched Patients
Wave 1* (n  207 Pairs) Wave 2* (n  396 Pairs)
HR† (95% CI) p Value HR† (95% CI) p Value
1.04 (0.66–1.64) 0.86 1.26 (0.85–1.87) 0.24
0.94 (0.60–1.47) 0.79 1.27 (0.86–1.87) 0.24
7.97 (3.34–19.00) 0.001 6.69 (3.44–13.03) 0.001
ersus concurrent CABG. †HRs are for the stenting group, as compared with CABG group.ABGWith
Pairs)
Value
0.91
0.94
0.001American College of Cardiology/American Heart Association Task
Force on Practice Guidelines (Committee to Update the 1999 Guide-
11
1
1
1
1
1
2
2
2
2
2
2
2
2
2
2
3
3
3
124 Park et al. JACC Vol. 56, No. 2, 2010
Stenting Versus CABG for LMCA Disease July 6, 2010:117–24lines for Coronary Artery Bypass Graft Surgery). J Am Coll Cardiol
2004;44:e213–311.
3. Laskey WK, Yancy CW, Maisel WH. Thrombosis in coronary
drug-eluting stents: report from the meeting of the Circulatory System
Medical Devices Advisory Panel of the Food and Drug Administra-
tion Center for Devices and Radiologic Health, December 7–8, 2006.
Circulation 2007;115:2352–7.
4. Robins JM, Hernan MA, Brumback B. Marginal structural models
and causal inference in epidemiology. Epidemiology 2000;11:550–60.
5. D’Agostino RB Jr. Propensity score methods for bias reduction in the
comparison of a treatment to a non-randomized control group. Stat
Med 1998;17:2265–81.
6. Gum PA, Thamilarasan M, Watanabe J, Blackstone EH, Lauer MS.
Aspirin use and all-cause mortality among patients being evaluated for
known or suspected coronary artery disease: a propensity analysis.
JAMA 2001;286:1187–94.
7. Chieffo A, Morici N, Maisano F, et al. Percutaneous treatment with
drug-eluting stent implantation versus bypass surgery for unprotected
left main stenosis: a single-center experience. Circulation 2006;113:
2542–7.
8. Lee MS, Kapoor N, Jamal F, et al. Comparison of coronary artery
bypass surgery with percutaneous coronary intervention with drug-
eluting stents for unprotected left main coronary artery disease. J Am
Coll Cardiol 2006;47:864–70.
9. Palmerini T, Marzocchi A, Marrozzini C, et al. Comparison between
coronary angioplasty and coronary artery bypass surgery for the
treatment of unprotected left main coronary artery stenosis (the
Bologna Registry). Am J Cardiol 2006;98:54–9.
0. Sanmartin M, Baz JA, Claro R, et al. Comparison of drug-eluting
stents versus surgery for unprotected left main coronary artery disease.
Am J Cardiol 2007;100:970–3.
1. Buszman PE, Kiesz SR, Bochenek A, et al. Acute and late outcomes
of unprotected left main stenting in comparison with surgical revas-
cularization. J Am Coll Cardiol 2008;51:538–45.
2. Brener SJ, Galla JM, Bryant R III, Sabik JF III, Ellis SG. Comparison
of percutaneous versus surgical revascularization of severe unprotected
left main coronary stenosis in matched patients. Am J Cardiol
2008;101:169–72. K3. White AJ, Kedia G, Mirocha JM, et al. Comparison of coronary artery
bypass surgery and percutaneous drug-eluting stent implantation for
treatment of left main coronary artery stenosis. J Am Coll Cardio Intv
2008;1:236–45.
4. Rodes-Cabau J, Deblois J, Bertrand OF, et al. Nonrandomized
comparison of coronary artery bypass surgery and percutaneous coro-
nary intervention for the treatment of unprotected left main coronary
artery disease in octogenarians. Circulation 2008;118:2374–81.
5. Serruys PW, Morice MC, Kappetein AP, et al. Percutaneous coronary
intervention versus coronary-artery bypass grafting for severe coronary
artery disease. N Engl J Med 2009;360:961–72.
6. Kappetein AP. Optimal revascularization strategy in patients with
three-vessel disease and/or left main disease: 2 year outcomes of the
SYNTAX trial. Paper presented at: ESC Congress 2009; August
29–September 2, 2009; Barcelona, Spain.
7. Taggart DP, Kaul S, Boden WE, et al. Revascularization for unpro-
tected left main stem coronary artery stenosis stenting or surgery. J Am
Coll Cardiol 2008;51:885–92.
8. Chieffo A, Park SJ, Meliga E, et al. Late and very late stent thrombosis
following drug-eluting stent implantation in unprotected left main
coronary artery: a multicentre registry. Eur Heart J 2008;29:2108–15.
9. Meliga E, Garcia-Garcia HM, Valgimigli M, et al. Longest available
clinical outcomes after drug-eluting stent implantation for unprotected
left main coronary artery disease: the DELFT (Drug Eluting stent for
LeFT main) Registry. J Am Coll Cardiol 2008;51:2212–9.
0. Vaquerizo B, Lefevre T, Darremont O, et al. Unprotected left main
stenting in the real world: two-year outcomes of the French left main
Taxus registry. Circulation 2009;119:2349–56.
1. Brinker J. The left main facts: faced, spun, but alas too few. J Am Coll
Cardiol 2008;51:893–8.
2. Tabata M, Grab JD, Khalpey Z, et al. Prevalence and variability of
internal mammary artery graft use in contemporary multivessel
coronary artery bypass graft surgery: analysis of the Society of
Thoracic Surgeons National Cardiac Database. Circulation 2009;
120:935– 40.ey Words: coronary disease y revascularization y stents y surgery.
